Table 3.
General linear model for analysis of variance of estimated glomerular filtration rate both among patients with and without non-alcoholic fatty liver disease
| Source |
Patients with NAFLD |
Patients without NAFLD |
||||
| Coefficient | F-ratio | P value | Coefficient | F-ratio | P value | |
| Model | 6.24 | < 0.0001 | 3.30 | 0.001 | ||
| Gender | -0.78 | 0.62 | 0.43 | 0.31 | 0.09 | 0.75 |
| Duration of obesity | -2.48 | 6.17 | 0.01 | -0.47 | 0.22 | 0.63 |
| HSD17B13 genotype | 1.89 | 42.58 | < 0.0001 | 4.63 | 21.49 | < 0.0001 |
| PNPLA3 genotype | -3.80 | 11.19 | 0.001 | -0.90 | 0.81 | 0.36 |
| TM6SF2 genotype | 1.13 | 11.82 | 0.001 | 1.40 | 1.97 | 0.16 |
| BMI-SDS | 0.62 | 0.38 | 0.53 | 0.51 | 0.26 | 0.61 |
| HOMA-IR | -1.20 | 1.44 | 0.23 | 0.63 | 0.40 | 0.52 |
| Triglycerides | -0.94 | 0.89 | 0.34 | 0.95 | 0.90 | 0.34 |
| LDL-Cholesterol | 0.69 | 0.47 | 0.49 | 0.23 | 0.05 | 0.81 |
NAFLD: Model r2 0.39, adjusted r2 0.33; Non NAFLD: Model r2 0.16, adjusted r2 0.11. ALT: Alanine transaminase; BMI: Body mass index; eGFR: Estimated glomerular filtration rate; GLM: General linear model; HOMA: Homeostasis model assessment; LDL: Low density lipoprotein; SDS: Standard deviation score.